Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 6 · inside the Ichimoku cloud · RSI 51 · MACD below its signal
None of the 29 investors followed here reported a position in ICU in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ICU trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.8 | 16.0 | 34.8 | 11.3 | -10.4 | -1.1 | -14.7 | 0.0 | 25.9 | -8.9 | +49.6% | ||
| 2025 | 15.5 | -22.8 | -4.0 | -22.3 | -7.8 | -64.2 | 43.0 | 50.4 | -37.8 | 0.0 | -44.4 | -24.3 | −87.6% |
| 2024 | 81.0 | -8.5 | 0.0 | -34.6 | -22.7 | -18.2 | 15.9 | -44.0 | -13.6 | -27.2 | -19.4 | -22.4 | −82.5% |
| 2023 | -2.8 | -25.5 | -37.4 | 15.6 | -75.8 | 0.0 | 0.2 | -49.7 | 0.8 | 211.0 | -38.0 | -13.0 | −89.2% |
| 2022 | -0.3 | 0.7 | 0.4 | 0.3 | -0.1 | 0.2 | 0.6 | 0.0 | 0.6 | 5.8 | -60.8 | -3.8 | −59.2% |
| 2021 | 1.3 | -0.6 | 0.3 | -0.8 | 0.9 | 1.2 | -0.5 | 0.9 | -0.3 | +2.3% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Messinger MichaelChief Financial Officer | Purchase at price 3.27 per share. | 750 | $2.45K |
| Jun 30, 2026 | Van Heel Kenneth J.Director | Stock Award(Grant) at price 0.00 per share. | 4K | — |
| Jun 30, 2026 | Schlorff EricChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 10.3K | — |
| Jun 30, 2026 | Chung KevinOfficer | Stock Award(Grant) at price 0.00 per share. | 7.2K | — |
| Jun 30, 2026 | Neuman JohnDirector | Stock Award(Grant) at price 0.00 per share. | 4K | — |
| Jun 30, 2026 | Baird Jennifer ADirector | Stock Award(Grant) at price 0.00 per share. | 4K | — |
| Jun 30, 2026 | Vincent Bernadette NDirector | Stock Award(Grant) at price 0.00 per share. | 4K | — |
| Feb 5, 2026 | Van Heel Kenneth J.Director | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Feb 5, 2026 | Towne Bradford KOfficer | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Feb 5, 2026 | Schlorff EricChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Feb 5, 2026 | Chung KevinOfficer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Feb 5, 2026 | Neuman JohnDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Feb 5, 2026 | Baird Jennifer ADirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Feb 5, 2026 | Vincent Bernadette NDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Dec 18, 2025 | Baird Jennifer ADirector | Purchase at price 0.24 per share. | 4.2K | $987 |
| Dec 8, 2025 | Messinger MichaelChief Financial Officer | Purchase at price 0.35 per share. | 14.5K | $5.10K |
| Aug 26, 2025 | Van Heel Kenneth J.Director | Purchase at price 0.86 - 0.89 per share. | 35K | $30.81K |
| Aug 21, 2025 | Chung KevinOfficer | Purchase at price 0.80 per share. | 10K | $8.00K |
| Jul 9, 2025 | Van Heel Kenneth J.Director | — | 4K | — |
| Jul 9, 2025 | Neuman JohnDirector | — | 4K | — |
Buy / hold / sell counts
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.